Monetary blood donation incentives and the risk of transfusion- transmitted infection

Transfusion

Volumn 38, Issue 9, 1998, Pages 874-882

  Eastlund, T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD DONOR; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; INFECTION RISK; MONEY; POLYMERASE CHAIN REACTION; REVIEW; UNITED STATES; VIRUS HEPATITIS; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0031694383     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1998.38998409009.x     Document Type: Review

References (106)

1. Domen RE. The confidential unit exclusion and allogeneic blood donation. Arch Pathol Lab Med 1995;119:1007-11.
2. Samson SM, Edmiston RK, Busch MP, Perkins HA. How well has donor call-back worked? (abstract). Transfusion 1993;33(Suppl):35S.
3. Saldanha J, Minor P. A sensitive PCR method for detecting HCV RNA in plasma pools, blood products and single donations. J Med Virol 1994;43:72-6.
4. Kleim JP, Bailly E, Schneweis KE, et al. Acute HIV-infection in patients with hemophilia B treated with B-propiolactone-UV-inactivated clotting factor. Thromb Haemost 1990;64:336-7.
5. Domen RE. Paid-versus-volunteer blood donation in the United States: a historical review. Transfus Med Rev 1995;9:53-9.
6. Condie S, Maxwell N. Comparative demographic profiles: voluntary and paid donors. Transfusion 1970;10:84-8.
7. Special report: FDA workshop focuses on plasma collection, donor remuneration issues. CCBC Newsletter 1993;July 9:2-4.
8. Leikola J. Non-remunerated donations. In: Brown F, ed. Virological safety aspects of plasma derivatives. Dev Biol Stand 1993;81:51-6.
9. Leikola J. Plasma procurement worldwide. Beitr Infusionsther 1989;24:69-73.
10. Britten AFH. Plasma procurement and fractionation: a worldwide overview. In: Kolins J, Britten AFH, Silvergleid AJ, eds. Plasma products: use and management: a technical workshop. Arlington: American Association of Blood Banks, 1982:1-22.
11. Britten AF, Ala F, Carman C, Smit Sibinga CT. Worldwide overview of plasma procurement and fractionation. Scand J Haematol 1984;33(Suppl 40):479-84.
12. Rodell M. Special report: FDA workshop focuses on plasma collection. CCBC Newsletter 1993;July 9:3.
13. Fricke W, Augustyniak L, Lawrence D, et al. Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance Project. Transfusion 1992;32:707-9.
14. Kumar A, Kulkarni R, Murray DL, et al. Serologic markers of viral hepatitis A, B, C and D in patients with hemophilia. J Med Virol 1993;41:205-9.
15. Bloom AL. AIDS and haemophilia. Biomed Pharmacother 1985;39:355-65.
16. Scheinberg IH, Kinney TD, Janeway CA. Homologous serum jaundice. A problem in the operation of blood banks. JAMA 1947;134:841-8.
17. Berk JE. Hepatitis following transfusion. Gastroenterology 1947;8:296-310.
18. Jennings ER, Hindman WM, Zak B, et al. The thymol turbidity test in screening of blood donors. Am J Clin Pathol 1957;27:489-502.
19. Loder M. The results of thymol turbidity and flocculation studies in blood donors and the development of viral hepatitis in recipients. N Y State J Med 1955;55:2361-2.
20. Allen JG, Dawson D, Sayman WA, et al. Blood transfusion and serum hepatitis: use of monochloroacetate as an antibacterial agent in plasma. Ann Surg 1959;150:455-68.
21. Kunin CM. Serum hepatitis from whole blood: incidence and relationship to source of blood. Am J Med Sci 1959;334:293-303.
22. Grady GF, Chalmers TC. Risk of post-transfusion viral hepatitis. N Engl J Med 1964;271:337-42.
23. Mirick GS, Ward R, McCollum RW. Modification of posttransfusion hepatitis by gamma globulin. N Engl J Med 1965;273:59-65.
24. Allen JG. Commercially obtained blood and serum hepatitis. Surg Gynecol Obstet 1970;131:277-81.
25. Nishioka K. Transfusion-transmitted HBV and HCV. Vox Sang 1996;70(Suppl 3):4-8.
26. Walsh JH, Purcell RH, Morrow AG, et al. Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer blood donor populations. JAMA 1970;211:261-5.
27. Prince, AM, Brotman B, Grady GF, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 1974;2:241-6.
28. Prince AM, Brotman B, Grady GF, et al. Post-transfusion viral hepatitis due to an agent or agents other than hepatitis B virus or hepatitis A virus. Impact on efficiency of present screening methods. In: Greenwalt TJ, Jamieson GA, eds. Transmissible disease and blood transfusions. New York: Grune & Stratton, 1975:129-40.
29. Grady GF, Bennett AJ. Risk of posttransfusion hepatitis in the United States. A prospective cooperative study. JAMA 1972;220:692-701.
30. Okochi K, Murakami S. Observations on Australia antigen in Japanese. Vox Sang 1968;15:374-85.
31. Goesser E, London T, Sutnick A, et al. Post-transfusion hepatitis and frequency of donor blood Australia antigen in population subgroups. Clin Res 1970;18:380.
32. Guardia J, Bacardi R, Hernandez JM, Martiniz JM. Screening blood donors for Au antigen. Lancet 1970;2:465.
33. Cherubin CE, Prince AM. Serum hepatitis specific antigen (SH) in commercial and volunteer sources of blood. Transfusion 1971;1:25-7.
34. Seeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. Gastroenterology 1977;72:111-21.
35. Prince AM, Szmuness W, Woods KR, Grady GF. Antibody against serum hepatitis antigen. N Engl J Med 1971;285:933-8.
36. Szmuness W, Prince AM, Brotman B, Hirsch RL. Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis 1973;127:17-25.
37. Froesner GG, Peterson DA, Holmes AW, Deinhardt FW. Prevalence of antibody to hepatitis B surface antigen in various populations. Infect Immun 1975;11:732-6.
38. Tabor E, Goldfield M, Black HC, Gerety RJ. Hepatitis Be antigen in volunteer and paid blood donors. Transfusion 1980;20:192-8.
39. Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972;77:691-9.
40. Koretz RL, Gitnick GL. Prevention of post-transfusion hepatitis. Role of sensitive hepatitis B antigen screening tests, source of blood and volume of transfusion. Am J Med 1975;59:754-60.
41. Hoofnagle JH, Gerety RJ, Thiel J, Barker LF. The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med 1976;88:102-13.
42. Federal Register 1978;43:2142.
43. Hollinger FB, Alter HF, Holland PV, Aach RD. Non-A, non-B posttransfusion hepatitis in the United States. In: Gerety RJ, ed. Non-A, non-B hepatitis. New York: Academic Press, 1981:49-70.
44. Seeff LB, Wright EC, Zimmerman HJ, et al. Post-transfusion hepatitis, 1973-1975: a Veterans Administration cooperative study. In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis. Philadelphia: Franklin Institute Press, 1978:371-81.
45. Aach RD, Lander JJ, Sherman LA, et al. Transfusion-transmitted viruses: interim analysis of hepatitis among transfused and non-transfused patients. In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis. Philadelphia: Franklin Institute Press, 1978:383-96.
46. Aach RD, Kahn RA. Post-transfusion hepatitis: current perspectives. Ann Intern Med 1980;92:539-46.
47. Aach RD, Szmuness W, Mosley JW, et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients. N Engl J Med 1981;304:989-94.
48. Prince AM, Brotman B, Inchauspe G, et al. Patterns and prevalence of hepatitis C virus infection in post-transfusion non-A, non-B hepatitis. J Infect Dis 1993;167:1296-301.
49. Rodriguez M, Riestra S, San Roman F, et al. Prevalence of antibody to hepatitis C virus in acute non-A, non-B hepatitis in patients from different epidemiological categories. Arch Virol Suppl 1992;4:319-20.
50. Mosley JW, Aach RD, Hollinger FB, et al. Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 1990;263:77-8.
51. Hepatitis C virus encoded antigen (recombinant C100-3). Data submitted to the United States Food and Drug Administration for licensure. Summary basis for approval. Emeryville, CA. Chiron Corporation, 1989.
52. Dawson G, Lesniewski R, Stewart JL, et al. Detection of antibodies to hepatitis C virus in U.S. blood donors. J Clin Microbiol 1991;29:551-6.
53. Jha J, Banerjee K, Arankalle VA. A high prevalence of antibodies to hepatitis C virus among commercial plasma donors from Western India. J Viral Hepatitis 1995;2:257-60.
54. Wu RR, Mizokami M, Lau JY, et al. Seroprevalence of hepatitis C virus infection and its genotype in Lanzhau, Western China. J Med Virol 1995;45:174-8.
55. Hayashi J, Yoshimura E, Nabeshima A, et al. Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. J Gastroenterol 1994;29:276-81.
56. Saldanha J, Minor P. Incidence of hepatitis C virus RNA in anti-HCV-negative plasma pools and blood products. Vox Sang 1996;70:232-4.
57. Saldanha J. Assays for viral sequences and their value in validation of viral elimination. Dev Biol Stand 1993;81:231-6.
58. Makris M, Garson JA, Ring CJ, et al. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 1993;81:1898-902.
59. Yu MY, Mason BL, Tankersly DL. Detection and characterization of hepatitis C RNA in immune globulins. Transfusion 1994;34:596-602.
60. Yu MY. Special report: FDA workshop focuses on plasma collection, donor remuneration issues. CCBC Newsletter 1993;July 9:2-4.
61. Dille BJ, Surowy TK, Gutierrez RA, et al. An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis 1997;175:458-61.
62. Abbott Laboratory report. CCBC Newsletter 1996;May 3:8.
63. Jarvis LM, Davidson F, Hanley JP, et al. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996;348:1352-5.
64. Hughes M, Lloyd J, Singleton J, Wagner I. HIV testing in California blood banks and plasma centers. First quarter, 1989. California Department of Health Services. Calif AIDS Update 1989;2:95-7.
65. Fiedler H. HIV seropositivity in paid blood donors (letter). Lancet 1992;339:551.
66. Sepulveda Amor J, de Lourdes Garcia M, Dominguez Torix JL, Valdespino Gomez JL. Prevention of HIV transmission through blood and blood products: experiences in Mexico. Bull Pan Am Health Organ 1989;23:108-14.
67. Hernandez JM, Argelagues E, Canivell M. HTLV-III antibody in paid plasma donors in Spain (letter). Lancet 1985;1:1389.
68. Mundee Y, Kamtorn N, Chaiyaphruk S, et al. Infectious disease markers in blood donors in northern Thailand. Transfusion 1995;35:264-7.
69. Singh YN, Malaviya AN, Tripathy SP, et al. Human immunodeficiency virus in the blood donors of Delhi, India. J Acquir Immune Defic Syndr 1990;3:152-4.
70. Special report: FDA workshop focuses on plasma collection. CCBC Newsletter 1993;July 9:4.
71. Volkow P, Lopez AM, Torres I. Plasma trade and the HIV epidemic (letter). Lancet 1997;349:327-8.
72. Avila C, Stetler H, Sepulveda J, et al. The epidemiology of HIV transmission among paid plasma donors, Mexico City, Mexico. AIDS 1989;3:631-3.
73. Donovan B. HIV transmission to a blood donor (letter). Lancet 1988;2:452.
74. Wu Z, Liu Z, Detels R. HIV-1 infection in commercial plasma donors in China (letter). Lancet 1995;346:61-2.
75. Jager H, Nseka K, Goussard B, et al. Voluntary blood donor recruitment: a strategy to reduce transmission of HIV-1, hepatitis-B and syphilis in Kinshasa, Zaire. Infusionstherapie 1990;17:224-6.
76. Canavaggio M, Leckie G, Allain JP, et al. The prevalence of antibody to HTLV-I/II in United States plasma donors and in United States and French hemophiliacs. Transfusion 1990;30:780-2.
77. Guerrero IC, Weniger BC, Schultz MG. Transfusion malaria in the United States, 1972-1981. Ann Intern Med 1983; 99:221-6.
78. Fiedler H. Anti-HIV rates in blood donations in Europe and the safety of its national blood supplies (letter). Vox Sang 1994;67:244.
79. Kliman A. Australia antigen in volunteer and paid blood donors (letter). N Engl J Med 1971;284:109.
80. Kliman A, Reid NR, Lilly C, et al. Hepatitis-associated antigen (Australia antigen) in Massachusetts blood donors. N Engl J Med 1971;285:783-5.
81. Nelson KE, Vlahov D, Margolick J, et al. Blood and plasma donations among a cohort of intravenous drug users. JAMA 1990;263:2194-7.
82. Chitwood DD, Page JB, Comerford M, et al. The donation and sale of blood by intravenous drug users. Am J Public Health 1991;81:631-3.
83. Miller WV. Paid blood donors (letter). N Engl J Med 1972;286:895.
84. Strauss RG, Ludwig GA, Smith MV, et al. Concurrent comparison of the safety of paid cytapheresis and volunteer whole-blood donors. Transfusion 1994;34:116-21.
85. Strauss RG, Floss AS, Eckermann I, Goeken JA. Carefully selected, paid donors can serve as a source of safe blood (abstract). Transfusion 1986;26:602.
86. Taswell HF. Directed, paid and self-donors. In: Clark GM, ed. Competition in blood services. Arlington: American Association of Blood Banks, 1987:137-48.
87. Ferrari JR, Barone RC, Jason LA, Rose T. The use of incentives to increase blood donations. J Soc Psychol 1985;125: 791-3.
88. Which criteria must be fulfilled for a donation or a donor to be considered 'voluntary'? Vox Sang 1978;34:362-71.
89. Mayo DJ. Evaluating donor recruitment strategies (editorial). Transfusion 1992;32:797-9.
90. Read EJ, Herron RM, Hughes DM. Effect of non-monetary incentives on safety of blood donations (abstract). Transfusion 1993;33(Suppl):45S.
91. Donor incentives - a report to the Board of Directors. AABB Association Bulletin 94-6. Bethesda: American Association of Blood Banks, 1994.
92. Williams AE, Thompson RA, Horton JA, Kleinman SH. Characterization of active blood donors who recently donated blood primarily to receive an HIV test (abstract). Transfusion 1995;35(Suppl):42S.
93. Special report: donor incentives discussed at FDA workshop. CCBC Newsletter 1996;September 27:9-15.
94. McFarland JG, Aster RH, Buggy BP. Paid time off for blood donation - an incentive to be less than truthful? (letter). Transfusion 1997;37:447-8.
95. Sun CF. Elimination of pay donation of blood in Taiwan (letter). Vox Sang 1994;66:242.
96. Surgenor DM, Cerveny JF. A study of the conversion from paid to altruistic blood donors in New Mexico. Transfusion 1978;18:54-63.
97. Leikola J. Self-sufficiency in blood products: background and overview. Plasma Ther Transfus Technol 1987;8:215-20.
98. Beal RW, van Aken WG. Gift or good? A contemporary examination of the voluntary and commercial aspects of blood donation. Vox Sang 1992;63:1-5.
99. Hewitt PE, Brennan M. Donors and dollars (letter). Transfusion 1994;34:837.
100. Britten AFH. A scheme for plasma management in a community blood center. In: Kolins J, Britten AFH, Silvergleid AJ, eds. Plasma products: use and management. Arlington: American Association of Blood Banks, 1982:109-26.
101. Kasper CK. Cryoprecipitate and factor VIII concentrate -aspects of production and use. In: Myhre BA, ed. A seminar on blood components: e unum pluribus. Washington: American Association of Blood Banks, 1977:111-7.
102. Mannucci PM. What is the importance of "small pool concept" in the preparation of fraction I and cryoprecipitates for the prevention of post-transfusion hepatitis? Vox Sang 1980;38:109-11.
103. Rodriguez del Pozo P. Paying donors and the ethics of the blood supply. J Med Ethics 1994;20:31-5.
104. Resolution 28.72. Utilization and supply of human blood products. Presented at the 28th World Health Assembly, Geneva, 1975.
105. Council of Europe. Guide to the preparation, use, and quality assurance of blood components. Directive 89/381/EEC. Strasbourg: Council of Europe Press, 1992.
106. Keown J. The gift of blood in Europe: an ethical defense of EC directive 89/381. J Med Ethics 1997;23:96-100.